What is it about?
We evaluated 200,000 different small molecules in a search for compounds that inhibit activity of the DUX4 protein.
Featured Image
Why is it important?
Small molecule inhibitors discovered through this type of screening approach are the typical lead compounds for pharmaceutical therapies. There is currently no pharmaceutical therapy for FSHD.
Perspectives
Read the Original
This page is a summary of: Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen, SLAS DISCOVERY, July 2016, SAGE Publications,
DOI: 10.1177/1087057116651868.
You can read the full text:
Contributors
The following have contributed to this page